PANAMutyper™ R technology is based on peptide nucleic acid (PNA)-mediated real-time PCR clamping
and melting peak analysis technology. By using wild type DNA specific PNA clamp probe, the
amplification of the wild type DNA is suppressed. In addition, by using mutant type DNA specific PNA detection probe which has fluorescent dye and quencher, a single mutation can be genotyped by
melting peak analysis.
Therefore, PANAMutyper™ R technology can detect a single base mutation accurately with high
sensitivity for only a minute amount of mutant type DNA, such as the samples from blood. It is also very fast and convenient method for detecting mutant.
Lung cancer is a metastatic cancer which the cancer cells are developed in the bronchial tubes or alveoli and grow along the blood vessel or lymphatic vessel. There are two types of lung cancer based on the sizes and shape of the cancer cell; non-small cell lung cancer (NSCLC) takes 75% and small cell lung cancer takes 25%. Usually, it is hard to find lung cancer in the early stage and is diagnosed as lung cancer when it is already progressed. So the prognosis tends to be bad. It is known that the patients with EGFR mutation show very high drug responses against EGFR tyrosine kinase inhibitor (TKI) such as Gefitinib (Iressa, AstraZenca) and Erlotinib (Tarceba, Roche). We expect that genotyping EGFR genes of the lung cancer patients enables predicting drug response before treatment and this will lead effective lung cancer treatment.
PANAMutyper™ R EGFR |
Product Name | Cat No. | Size | PANAMutyper™ R EGFR (47 Mutations) | PNAR-3001 | 24 tests | | | | | |
|
|
EGFR Mutation Details |
No. | Reagent | Exon | Amino Acid Change | Nucleotide change | Cosmic No. |
---|
|
1 | G719 | E18 | G719A | c.2156G>C | 6239 | 2 | G719S | c.2155G>A | 6252 | 3 | G719C | c.2155G>T | 6253 | 4 | E19del A | 19 | p.E746_A750del | c.2235_2249 del 15 | 6223 | 5 | p.E746_A750del | c.2236_2250 del 15 | 6225 | 6 | p.E746_T751>IP | c.2235_2251>AATTC | 13552 | 7 | p.K745_E749del | c.2233_2247 del 15 | 26038 | 8 | p.E746_T751>I | c.2235_2252 AAT (complex) | 13551 | 9 | p.E746_A750del | c.2235_2248>AATTC | 13550 | 10 | p.L747_S752>Q | c.2239_2256>CAA | 12403 | 11 | p.S752_I759del | c.2253_2276 del 24 | 12416 | 12 | p.E746_T751>VA | c.2237_2253>TTGCT | 12422 | 13 | p.E746_T751>A | c.2237_2251 del 15 | 12678 | 14 | p.L747_T751del | c.2239_2253 del 15 | 6254 | 15 | p. L747_T751del | c.2238_2252 del 15 | 23571 | 16 | p.L747_T751>Q | c.2238_2252>GCA(complex) | 12419 | 17 | E19del B | 19 | p.L747_T751del | c.2240_2254 del 15 | 12369 | 18 | p.L747_T751del | c.2239_2253 del 15 | 6254 | 19 | p.E746_T751>V | c.2237_2252>T | 12386 | 20 | p.E746_S752>I | c.2235_2255>AAT | 12385 | 21 | p.L747_T751del | c.2238_2252 del 15 | 23571 | 22 | p.E746_T751del | c.2236_2253 del 18 | 12728 | 23 | p.E746_S752>A | c.2237_2254 del 18 | 12367 | 24 | p.E746_S752>V | c.2237_2255>T (complex) | 12384 | 25 | p.E746_S752>D | c.2238_2255 del 18 | 6220 | 26 | p.L747_A750>P | c.2238_2248>GC(complex) | 12422 | 27 | p.L747_E749del | c.2239_2247 del 9 | 6218 | 28 | p.L747_S752del | c.2239_2256 del 18 | 6255 | 29 | p.L747_ A750>P | c.2239_2248 TTAAGAGAAG>C | 12382 | 30 | p.L747_P753>Q | c.2239_2258>CA(complex) | 12387 | 31 | p.L747_T751>S | c.2240_2251 del 12 | 6210 | 32 | p.L747_P753>S | c.2240_2257 del 18 | 12370 | 33 | p.L747_T751>P | c.2239_2251>C(complex) | 12383 | 34 | p.E746_P753>VS | c.2237_2257>TCT | 18427 | 35 | S768I | 20 | S768I | c.2303G>T | 6241 | 36 | T790M | 20 | T790M | c.2369C>T | 6240 | 37 | E20ins A | 20 | p.D770_N771insG | c.2310_2311 insGGT | 12378 | 38 | p.P772_H773insTTP | c.2315_2316 insGACAACCCC | | 39 | p.P772_H773insGNP | c.2315_2316 insGGGCAACCC | | 40 | p.V769_N770insASV | c.2309_2310 AC>CCAGCGTGGAT | 13558 | 41 | E20ins B | 20 | p.V769_D770insASV | c.2307_2308 ins GCCAGCGTG | 12376 | 42 | p.H773_V774insH | c.2319_2320 insCAC | 12377 | 43 | p.H773L | c.2318 A>T | 13005 | 44 | p.H773_V774insPH | c.2319_2320 insCCCCAC | 12380 | 45 | p.V774_C775insHV | c.2321_2322 insCCACGT | 18432 | 46 | p.D770_N771insSVD | c.2311_2312 ins GCGTGGACA | 13428 | 47 | L858R | 21 | L858R | c.2573T>G | 6224 | 48 | L858R | c.2573_2574 TG>GT | 12429 | 49 | L861Q | L861Q | c.2582T>A | 6213 |
|
KRAS mutation is found in several cancers such as pancreatic cancer, colorectal cancer, lung cancer, biliary tract cancer and thyroid cancer. The existence of KRAS mutations is often related with a prognostic marker to drug response. For example, KRAS mutation is considered a strong prognostic marker for drug response of tyrosine kinase inhibitors such as Gefitinib (Iressa) or Erlotinib (Tarceva).Recently, KRAS mutation is often detected in colorectal cancer and may be related with drug responseto Cetuximab (Erbitux) or Panitumumab (Vectibix) that is used for colon cancer therapy. Therefore,examination of KRAS mutation is needed to determine drug resistance of patients with colorectal or lung cancers and will be helpful for cancer therapies.
PANAMutyper™ R KRAS |
Product Name | Cat No. | Size | PANAMutyper™ R KRAS (29 Mutations) | PNAR-1001 | 24 tests | | | | | |
|
|
KRAS Mutation Details |
No. | Reagent | Codon | Amino Acid Change | Nucleotide change | Cosmic No. |
---|
1 | KC12a | 12 | p.G12A | c.35G>C | 522 | 2 | p.G12V | c.35G>T | 520 | 3 | p.G12R | c.34G>C | 518 | 4 | p.G12C | c.34G>T | 516 | 5 | KC12b | p.G12D | c.35G>A | 521 | 6 | p.G12S | c.34G>A | 517 | 7 | 7 | 13 | p.G13A | c.38G>C | 533 | 8 | p.G13V | c.38G>T | 534 | 9 | p.G13R | c.37G>C | 529 | 10 | p.G13C | c.37G>T | 527 | 11 | KC13b | p.G13D | c.38G>A | 532 | 12 | p.G13S | c.37G>A | 528 | 13 | KC59 | 59 | p.A59T | c.175G>A | 546 | 14 | p.A59E | c.176C>A | 547 | 15 | p.A59G | c.176C>G | 28518 | 16 | KC61 | 61 | p.Q61K | c.181C>A | 549 | 17 | p.Q61E | c.181C>G | 550 | 18 | p.Q61P | c.182A>C | 551 | 19 | p.Q61R | c.182A>G | 552 | 20 | p.Q61L | c.182A>T | 553 | 21 | p.Q61H | c.183A>C | 554 | 22 | p.Q61H | c.183A>T | 555 | 23 | KC117 | 117 | p.K117E | c.349A>G | 1360831 | 24 | p.K117N | c.351A>C | 19940 | 25 | p.K117N | c.351A>T | 28519 | 26 | KC146 | 146 | p.A146T | c.436G>A | 19404 | 27 | p.A146P | c.436G>C | 19905 | 28 | p.A146G | c.437C>G | 1360829 | 29 | p.A146V | c.437C>T | 19900 |
|
NRAS mutation is found in several cancers such as melanoma (13~25%), colorectal cancer (1~6%), lung cancer (1%), thyroid cancer (7%) and hepatocellular carcinoma (10%). It is know that the drug response against colorectal cancer medicine such as Erbitux and Cetuximab decreased and the prognosis of the metastatic colorectal cancer patient is bad if the patient has NRAS mutation. Recently, there are some papers that report the drug responses can be different for the NRAS mutation type so it is important to genotype each mutation. NRAS gene mutation genotyping test is necessary especially for predicting the drug sensitivity and prognosis. This test expected to play a major role for predicting the treatment of the patients and prognosis.
PANAMutyper™ R NRAS |
Product Name | Cat No. | Size | PANAMutyper™ R NRAS (31 Mutations) | PNAR-1101 | 24 tests | | | | | |
|
|
NRAS Mutation Details |
No. | Reagent | Codon | Amino Acid Change | Nucleotide change | Cosmic No. |
---|
1 | NC12a | 12 | p.G12A | c.35G>C | 565 | 2 | p.G12V | c.35G>T | 566 | 3 | p.G12R | c.34G>C | 561 | 4 | p.G12C | c.34G>T | 562 | 5 | NC12b | p.G12D | c.35G>A | 564 | 6 | p.G12S | c.34G>A | 563 | 7 | NC13a | 13 | p.G13A | c.38G>C | 575 | 8 | p.G13V | c.38G>T | 574 | 9 | p.G13R | c.37G>C | 569 | 10 | p.G13C | c.37G>T | 570 | 11 | NC59 | p.G13D | c.38G>A | 573 | 12 | p.G13S | c.37G>A | 571 | 13 | NC59 | 59 | p.A59T | c.175G>A | 578 | 14 | p.A59D | c.176C>A | 253327 | 15 | p.A59A | c.177T>C | 1332932 | 16 | NC61 | 61 | p.Q61R | c.182A>G | 584 | 17 | p.Q61K | c.181C>A | 580 | 18 | p.Q61L | c.182A>T | 583 | 19 | p.Q61H | c.183A>T | 585 | 20 | p.Q61H | c.183A>C | 586 | 21 | p.Q61P | c.182A>C | 582 | 22 | p.Q61E | c.181C>G | 581 | 23 | NC117 | 117 | p.K117E | c.349A>G | | 24 | p.K117R | c.350A>G | | 25 | p.K117N | c.351G>C | | 26 | p.K117N | c.351G>T | | 27 | NC146 | 146 | p.A146T | c.436G>A | 27174 | 28 | p.A146P | c.436G>C | | 29 | p.A146S | c.436G>T | | 30 | p.A146V | c.437C>T | 4170228 | 31 | p.A146G | c.437C>G | |
|
Please email the quote request to order@pnabio.com or click "Inquire" button below.
Catalog No | Product Name | Description | Size | Price |
PNAR-1001 | PANAMutyper™ R KRAS | MutyperR for KRAS 29 mutations | 24 tests | inquire |
PNAR-1101 | PANAMutyper™ R NRAS | MutyperR for NRAS 31 mutations | 24 tests | inquire |
PNAR-3001 | PANAMutyper™ R EGFR | MutyperR for EGFR 47 mutations | 24 tests | inquire |